Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arbor's Bid For XenoPort Likely Driven By Effort To Grow Horizant

This article was originally published in The Pink Sheet Daily

Executive Summary

With minimal unencumbered pipeline assets to offer, XenoPort's value to Arbor apparently lies in positive sales trends for the modest-selling restless legs and postherpetic neuralgia drug.

You may also be interested in...



Deal Watch: Arbor Betting On Building Horizant Commercially As Xenoport Couldn't

Ireland's Jazz pays $1.5bn to acquire Celator and its hotly anticipated leukemia drug, Vyxeos; Spero takes over antibacterial program out-licensed by Vertex; Novartis to copromote Eisai's Lenvima.

Deerfield Management Opts For More Private Investment And A New Public Face

Deerfield Management, the $3.5 billion health care hedge fund, is aggressively expanding its investments in private life sciences companies. As many VCs continue to struggle raising new funds Deerfield hopes its shift, combined with a flexible, research-driven approach to investing and a new involvement in the civic and academic activities shaping the sector, will secure its position as a top health care financier.

FDA Approves Horizant For Restless Legs Syndrome, Bringing Relief To XenoPort, Revenues To GSK

The California biotech likely to get a lifeline, while GSK will benefit from incremental revenues, but the market, including payers, has to yet to be educated.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel